Journal of Diabetes and Its Complications
Volume 17, Issue 4 , Pages 211-217 , July 2003

Combination therapy with pioglitazone plus metformin or sulfonylurea in patients with Type 2 diabetes: Influence of prior antidiabetic drug regimen

  • Marc S. Rendell

      Affiliations

    • Creighton Diabetes Center, Omaha, NE, USA
    • ,
  • N.Bradly Glazer

      Affiliations

    • Takeda Pharmaceuticals North America, 475 Half Day Road, Suite 500, Lincolnshire, IL 60069, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-847-383-3227; fax: +1-847-383-3056
    • ,
  • Zhan Ye

      Affiliations

    • Takeda Pharmaceuticals North America, 475 Half Day Road, Suite 500, Lincolnshire, IL 60069, USA

Received 11 December 2002 ,Accepted 9 January 2003.

References 

  1. ACTOS [package insert] (2002). Lincolnshire, IL: Takeda Pharmaceuticals North America.
  2. American Diabetes Association. Tests of glycemia in diabetes. Diabetes Care. 2002;25(Suppl. 1):S97–S99
  3. Chow CC, Tsang LW, Sorensen JP, Cockram CS. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients. Diabetes Care. 1995;18:307–314
  4. Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL  The Pioglitazone 027 Study Group. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: A randomized, placebo-controlled study. Clinical Therapeutics. 2000;22:1395–1409
  5. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: A randomized controlled trial. JAMA. 2000;283:1695–1702
  6. Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. New England Journal of Medicine. 1998;338:867–872
  7. Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: A randomized, placebo-controlled study. American Journal of Medicine. 2001;111:10–17
  8. Sugiyama Y, Shimura Y, Ikeda H. Effects of pioglitazone on hepatic and peripheral insulin resistance in wistar fatty rats. Arzneimittelforschung. 1990;40:436–440
  9. Turner RC, Cull CA, Frighi V, Holman RR  UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281:2005–2012

PII: S1056-8727(03)00005-9

doi: 10.1016/S1056-8727(03)00005-9

Journal of Diabetes and Its Complications
Volume 17, Issue 4 , Pages 211-217 , July 2003

Article Tools

* Image Usage & Resolution